Alnylam Pharmace. buy Citigroup Inc.
Summary
This prediction is currently active. With a performance of 2.98%, the BUY prediction by Citigroup_Inc_ for Alnylam Pharmace. is trending in the right direction. This prediction currently runs until 25.06.25. The prediction end date can be changed by Citigroup_Inc_ at any time. Citigroup_Inc_ has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
Name | 1w |
---|---|
Alnylam Pharmace. | -1.429% |
iShares Core DAX® | 1.133% |
iShares Nasdaq 100 | 0.815% |
iShares Nikkei 225® | 1.990% |
iShares S&P 500 | -0.014% |
Comments by Citigroup_Inc_ for this prediction
In the thread Alnylam Pharmace. diskutieren
Stopped prediction by Citigroup_Inc_ for Alnylam Pharmace.
Alnylam Pharmace.
16.02.24
16.02.25
05.07.24